Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Good Life Advisors LLC

Good Life Advisors LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 304 shares of the biopharmaceutical company’s stock after selling 80 shares during the quarter. Good Life Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $217,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Financial Perspectives Inc lifted its position in shares of Regeneron Pharmaceuticals by 10.9% during the 4th quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 19 shares during the last quarter. Alberta Investment Management Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $5,058,000. Klingman & Associates LLC lifted its position in shares of Regeneron Pharmaceuticals by 13.2% during the 4th quarter. Klingman & Associates LLC now owns 291 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 34 shares during the last quarter. Callahan Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $617,000. Finally, Cardinal Capital Management lifted its position in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 7,871 shares of the biopharmaceutical company’s stock valued at $5,607,000 after acquiring an additional 36 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on REGN shares. Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Finally, Royal Bank of Canada reduced their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Trading Up 0.6 %

Regeneron Pharmaceuticals stock opened at $700.33 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market capitalization of $76.56 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 2.30 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company’s fifty day moving average price is $699.40 and its two-hundred day moving average price is $883.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $11.86 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.